REVB Revelation Biosciences reports vastly wider Q4 2025 loss than estimates shares end flat for the trading day Xenon Pharmaceuticals XENE Unveils Robust Azetukalner Phase III Data Q3 NDA Filing Plans at Bloom Burton Conference BLW Blackrock emphasizes targeted fixed income positioning to deliver stable returns across coming reporting quarters